GAVI announces HPV vaccine price reduction in less developed countries

The GAVI Alliance has announced a deal with Merck and GlaxoSmithKline that dramatically reduces the price of HPV vaccines in less developed countries. In these countries, the price of Gardasil has been reduced to $4.50 (USD) per dose, and Cervarix to $4.60 per dose. Prior to this public-private partnership agreement between GAVI and the HPV vaccine manufacturers, the lowest public sector price was $13 per dose.

This agreement is an important–and exciting–step in protecting girls in less developed countries from cervical cancer. More information on this program is available through GAVI’s website.